Trial reportBone marrow transplantation2017
Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD.
Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025Review
- Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024Review
- Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.Life (Basel, Switzerland) · 2024Article
- Corneal Descemetocele Management with Multi-Layer Amniotic Membrane Transplantation in an Ocular Graft-versus-Host Disease Case.Medicina (Kaunas, Lithuania) · 2023Article
- The ocular graft-versus-host disease: the path from current knowledge to future managements.Eye (London, England) · 2023Review
- A brief account on ocular graft versus host disease.Indian journal of ophthalmology · 2023Review
- Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.Frontiers in medicine · 2023Review
- A review of current advancements for wound healing: Biomaterial applications and medical devices.Journal of biomedical materials research. Part B, Applied biomaterials · 2022Review
- A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.Ophthalmology science · 2022Article
- Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease.International journal of molecular sciences · 2021Review
- Update on ocular graft-versus-host disease.Indian journal of ophthalmology · 2021Review
- Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.Journal of clinical medicine · 2019Review
- Bioactive Medications for the Delivery of Platelet Derivatives to Skin Wounds.Current drug delivery · 2019Review
- Characterization of induced pluripotent stem cell-derived megakaryocyte lysates for potential regenerative applications.Journal of cellular and molecular medicine · 2018Article
- Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease.Transfusion · 2018Article
- Association of Alpha Tocopherol and Ag Sulfadiazine Chitosan Oleate Nanocarriers in Bioactive Dressings Supporting Platelet Lysate Application to Skin Wounds.Marine drugs · 2018Article
- Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Review
- Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.Current opinion in ophthalmology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2-3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5-72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P<0.001). Median Tear Break Up Time improved from 3 to 6 s after 6 months and was maintained over time. All signs improved at 6 and 36 months (clinical and statistical significance). No severe adverse events occurred. Long-term treatment with PL drops is secure and effective for oGvHD and can be an efficient therapy option from initial stages of oGvHD to prevent permanent ocular impairment and improving quality of life.
Indexed as
Identifiers
27595285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.